using a Wilcoxon signed rank test. All statistical analyses were assessed with the SPSS version 23.0 (IBM Corp., Armonk, NY, USA). A P-value of <0.05 was considered statistically significant.
Ten patients were treated with MTX for active refractory
The conventional treatments for intestinal Behçet's disease (BD) include 5-aminosalicylic acids (5-ASAs), systemic corticosteroids, and immunosuppressive agents such as thiopurines. However, long-term use of corticosteroids is associated with steroid dependency and resistance, requiring additional immunosuppressant therapy or surgery. Azathioprine and 6-mercaptopurine (6-MP) are associated with bone marrow suppression and reported to occur in 56.4% after treatment with the maximal doses of azathioprine and 6-MP in Korean patients with IBD, which was a considerably higher incidence than that reported in Western studies. 1 Furthermore, BD may be associated with myelodysplastic syndrome, which might hamper the use of thiopurines in such patients. As intestinal BD is often refractory to these agents, the use of anti-tumor necrosis factor-α (anti-TNF-α) agents such as infliximab and adalimumab has recently been encouraged for the management of intestinal BD. A modest increase in the incidence of serious infection with biologics has been observed in methodologically rigorous studies.
2 Methotrexate (MTX), an analogue of folic acid and aminopterin, has antineoplastic function at high doses and inhibits lymphocyte proliferation and pro-inflammatory cytokines at low doses. MTX is currently being increasingly used in combination with anti-TNF-α agents to prevent immunogenicity in patients with CD. tions for MTX therapy were as follows: thiopurine intolerance, 10%; failure of anti-TNF-α agents, 60%; and corticosteroid dependence, 30% of patients. The administration route was oral in 8 patients, and SC or intramuscular (IM) route in 2 patients. The mean MTX dose for refractory intestinal BD was 13.0 mg (median, 12.5 mg; range, 7.5−20.0 mg) ( Table 2 ). The mean maintenance duration was 7.9±5.0 months (median, 6.5 months; range, 3−20 months). The reasons for discontinuing MTX were clinical inefficiency in 3 patients and self-interruption in 1 patient. One patient underwent major surgery while on MTX and 4 patients required hospitalization because of severe abdominal pain. Table 1 Values are presented as mean±SD or number (%). IC, ileocecal; TNF, tumor necrosis factor; DAIBD, disease activity index for intestinal Behçet's disease. Of the 10 patients receiving MTX, 3 patients (30%) achieved steroid-free remission at 3 months. Moreover, of the 8 patients receiving MTX for >6 months, 4 patients (50%) achieved steroid-free remission at 6 months. The mean DAIBD score was 82.5±36.8 at baseline. This decreased to 72.5±40.7 at 3 months and to 68.8±51.5 at 6 months; however, there was no significant difference (P=0.309). The mean CRP level was 38.0±36.1 mg/L at baseline. This decreased to 16.1±28.5 mg/L at 3 months and to 6.7±7.2 mg/L at 6 months, showing a statistical significance between 0 and 6 months (P =0.039) (Fig. 1A) . The mean ESR level was 57.8±36.0 mm/hr at baseline. This decreased to 42.8±36.8 mm/hr at 3 months and to 30.4±28.5 mm/hr at 6 months, showing no significant difference (P=0.078) (Fig. 1B) . Eight patients were administered MTX after 6 months, and 2 patients (25.0%) presented a relapse during this treatment. One patient underwent major surgery (right hemicolectomy) due to bowel perforation during MTX combination therapy and the other 1 patient underwent admission to control abdominal pain during MTX monotherapy. No serious adverse events were observed during 6 months of treatment. Nausea was reported by 20% of the patients.
Our study is the first to demonstrate the efficacy and tolerability of MTX monotherapy and MTX and adalimumab combination therapy. Three patients (30%) at 3 months and 4 patients (50%) at 6 months responded to MTX, achieving steroid-free remission. Furthermore, the serum CRP level was significantly decreased at 6 months compared with the baseline. The serum ESR and DAIBD score tended to decrease; however, there were no statistically significant differences. In 1987, a dose of 25 mg MTX was first used for patients with IBD, administered through the IM route for 12 weeks and then switched to a 7.5 mg oral formulation. Kozarek et al. 5 reported that in 16 of 31 patients with IBD, the corticosteroid dose could be tapered considerably. In a recent Cochrane review, IM MTX had a significant effect in patients with CD. Ardizzone et al. 6 reported that 25 mg/ week MTX is effective in inducing remission in patients with chronic active CD, with a therapeutic efficacy being comparable to that of 2 mg/kg/day azathioprine after 3 months (44% vs. 33%, P=0.28) and 6 months (56% vs. 63%, P=0.39). Moreover, Mate-Jimenez et al. suggested that 1.5 mg/kg/day 6-MP or 15 mg/week MTX added to prednisolone could be effective in maintaining remission in patients with steroiddependent CD (53.3% vs. 66.6%, P<0.001). 7 Both trials had a small size; however, they showed a similar efficacy of MTX to that of thiopurines. The advantage with the use of MTX is that cancer incidence is lower than that with azathioprine and the frequency of bone marrow suppression is low. MTX might be superior to azathioprine because intestinal BD is often accompanied by myelodysplastic syndrome with bone marrow dysfunction. 8 Furthermore, MTX is currently being increasingly used in combination with anti-TNF-α agents for patients with IBD to prevent immunogenicity. In COMMIT (Combination of Maintenance of Methotrexate-Infliximab Trial), patients with CD who received MTX were found to be less likely to develop antibodies to infliximab than those who received infliximab alone (4% vs. 20%, P=0.01).
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This study has several limitations. First, it was a retrospective, cross-sectional, and small study that was based on a medical record review. We could not draw a concrete conclusion that MTX monotherapy is effective in refractory intestinal BD because the number of patients is not enough. Nevertheless, we could report the possibility of MTX for patients with refractory BD by analyzing a well-organized, large database containing laboratory data and disease severity score index. Second, data were collected from a single tertiary hospital, which might limit the generalization of our findings to the general population. However, our center treats the greatest pool of patients with BD in Korea, and as patients with intestinal BD mostly visit tertiary hospitals, we believe that the bias was minimal. MTX is an effective drug for inducing and maintaining remission in CD, and it is an efficient drug both as a monotherapy and a combination therapy with an anti-TNF-α agent (to prevent immunization). The use of MTX in intestinal BD has not yet been established because of insufficient evidence. On the basis of our study, MTX might be an effective treatment for refractory intestinal BD. Further larger studies would be necessary to validate our conclusion.
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